Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Novavax is expected to post a loss of $0.08 per share ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Novavax is expected to post a loss of $0.12 per ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax Inc. closed 60.53% below its 52-week high of $17.81, which the company reached on July 26th.

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Novavax (NASDAQ:NVAX) on Wednesday announced late-stage trial data to indicate that its COVID-19-Influenza Combination (CIC) vaccine candidate and its stand-alone influenza vaccine candidate generated ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Novavax Inc. closed 61.03% short of its 52-week high of $17.81, which the company achieved on July 26th.